UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

British journal of haematology, 2013-07, Vol.162 (2), p.229-239

2013

Link zum Volltext

Verfügbarkeit prüfen

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

EJHaem, 2022-11, Vol.3 (4), p.1346-1351

2022

Link zum Volltext

Verfügbarkeit prüfen

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.787-798

2012

Link zum Volltext

Verfügbarkeit prüfen

Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F‐ and MPLW515 L‐positive myelofibrosis

Genes chromosomes & cancer, 2019-11, Vol.58 (11), p.747-755

2019

Link zum Volltext

Verfügbarkeit prüfen

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

Cancers, 2023-05, Vol.15 (10), p.2859

2023

Link zum Volltext

Verfügbarkeit prüfen

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

Experimental hematology & oncology, 2015-09, Vol.4 (1), p.26-26, Article 26

2015

Link zum Volltext

Verfügbarkeit prüfen

MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S404-S404

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Leukemia, 2021-12, Vol.35 (12), p.3455-3465

2021

Link zum Volltext

Verfügbarkeit prüfen

Managing patients with myelofibrosis and low platelet counts

Annals of Hematology, 2017-04, Vol.96 (4), p.537-548

2017

Link zum Volltext

Verfügbarkeit prüfen

Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

Leukemia & lymphoma, 2021-03, Vol.62 (4), p.918-926

2021

Link zum Volltext

Verfügbarkeit prüfen

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

Haematologica (Roma), 2016-12, Vol.101 (12), p.e482-e484

2016

Link zum Volltext

Verfügbarkeit prüfen

MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S390-S390

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis

Future oncology (London, England), 2022-09, Vol.18 (27), p.2987

2022

Link zum Volltext

Verfügbarkeit prüfen

MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S391-S392

2023

Link zum Volltext

Verfügbarkeit prüfen

MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22 Suppl 2, p.S339-S340

2022

Link zum Volltext

Verfügbarkeit prüfen

MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22 Suppl 2, p.S340

2022

Link zum Volltext

Verfügbarkeit prüfen

Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F‐ and MPLW515L‐positive myelofibrosis

Genes chromosomes & cancer, 2019-11, Vol.58 (11), p.747-755

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

ThemaMyelofibrosis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Anemia
(11)
Humans
(11)
Hematology
(9)
Oncology
(9)
Ruxolitinib
(9)
Patients
(8)
Primary Myelofibrosis - Drug Therapy
(8)
Thrombocytopenia
(8)
Spleen
(7)
Aged
(5)
Female
(5)
Jak Inhibitor
(5)
Male
(5)
Mpn
(5)
Pyrazoles - Therapeutic Use
(5)
Treatment Outcome
(5)
Aged, 80 And Over
(4)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F‐ and MPLW515 L‐positive myelofibrosis

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Managing patients with myelofibrosis and low platelet counts

Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis

MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study

MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor

MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]

Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F‐ and MPLW515L‐positive myelofibrosis

Aktive Filter

Suchergebnisse filtern